Literature DB >> 24583312

Molecular modeling and molecular dynamics simulations of GPI 14 in Leishmania major: insight into the catalytic site for active site directed drug design.

Sonali Shinde1, Milsee Mol1, Virashree Jamdar1, Shailza Singh2.   

Abstract

Leishmania major causes cutaneous form of Leishmaniasis affecting 21 million people in developing countries. Overuse of the chemotherapeutics against leishmaniasis has resulted in the development of drug resistance in the parasite. To surmount this emerging threat we have attempted to target the surface molecules. Glycosylphosphatidylinositol is one such molecule that is present abundantly and thus our work revolves around the enzyme mannosyltransferase (GPI 14), an enzyme essential to add mannose on the glycosylphosphatidyl. It has been targeted for drug discovery on account of growing resistance to miltefosine in L. major. This paper serves as the first attempt to detect GPI 14 gene in L. major supported with modeling and molecular dynamic analysis of complete three dimensional structure of GPI 14. The functional analysis revealed multiple transmembrane regions in GPI 14 and a close phylogenetic relation with Trypanosoma species and Schistosoma mansoni with highest bootstrap values. The protein model obtained was subjected to minimization for 14ns simulation. Eight derivatives of N-4-(-5(trifluromethyl)-1-methyl-1H benzo[d]imidazole-2 yl) phenyl) were docked onto GPI 14. The contact frequency of GPI 14 with the docked compounds suggested the inhibition of mannosylation proposing the druggability for leishmaniasis therapy.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cutaneous leishmaniasis; Docking; GPI biosynthesis; Gene expression; Phylogeny

Mesh:

Substances:

Year:  2014        PMID: 24583312     DOI: 10.1016/j.jtbi.2014.02.017

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  4 in total

1.  Genome-wide analysis reveals allelic variation and chromosome copy number variation in paromomycin-resistant Leishmania donovani.

Authors:  Sushmita Ghosh; Vinay Kumar; Aditya Verma; Tanya Sharma; Dibyabhaba Pradhan; Angamuthu Selvapandiyan; Poonam Salotra; Ruchi Singh
Journal:  Parasitol Res       Date:  2022-09-03       Impact factor: 2.383

Review 2.  Metabolic Pathways of Leishmania Parasite: Source of Pertinent Drug Targets and Potent Drug Candidates.

Authors:  Surbhi Jain; Utkarsha Sahu; Awanish Kumar; Prashant Khare
Journal:  Pharmaceutics       Date:  2022-07-30       Impact factor: 6.525

3.  Improved orthologous databases to ease protozoan targets inference.

Authors:  Nelson Kotowski; Rodrigo Jardim; Alberto M R Dávila
Journal:  Parasit Vectors       Date:  2015-09-29       Impact factor: 3.876

4.  Mannosyltransferase (GPI-14) overexpression protects promastigote and amastigote forms of Leishmania braziliensis against trivalent antimony.

Authors:  Christiana Vargas Ribeiro; Bruna Fonte Boa Rocha; Douglas de Souza Moreira; Vanessa Peruhype-Magalhães; Silvane Maria Fonseca Murta
Journal:  Parasit Vectors       Date:  2019-01-25       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.